Biomarker ID 2536 |
| Detailed information | |
|---|---|
| CancerLivER ID | 2536 |
| Biomarker | AF147376, FLJ20084, LRP8, DKK2, AK027155, AK002039, PLSCR4, AK021998, ESDN, AKR7A2, MAP2K2, AL133075, APOL3, AK023559, GNRHR, COQ6, AF086143, FLJ14117, HUMCYT2A, D25272, M37712, KLK12, ZNF205, NM_001758, AK001102, KIAA0562, CIAO1, SRRM2, UBE1, FBXO10, AF113699, APOB, D86974, Z70704, SFRS2IP, WDFY1, |
| Biomarker Name/Symbol (given in Publication) | 120 genes-signature ( AF147376, FLJ20084, LRP8, DKK2, AK027155, AK002039, PLSCR4, AK021998, ESDN, AKR7A2, MAP2K2, AL133075, APOL3, AK023559, GNRHR, COQ6, AF086143, FLJ14117, HUMCYT2A, D25272, M37712, KLK12, ZNF205, NM_001758, AK001102, KIAA0562, CIAO1, SRRM2, UBE1, FBXO10, AF113699, APOB, D86974, Z70704, SFRS2IP, WDFY1, AF147325, EWSR1, DKFZP564O0823, KIAA0625, C6orf11, NM_016411, NHP2L1, IGSF4, IPO11, KIAA1194, LOC51319, DCTN4, DKFZP564K1964, HPRP8BP, NM_006648, DNMT2, MRPS7, RNASEP1, FLJ11280, MRPL30, FLJ10407, LOC90355, PDCL, MYCBP, GPRK5, AK021723, AK022461, M57417, EIF5A, PC-LKC, AK000561, IGF2, GSTZ1, ADRB3, MYR8, AK024225, MTRR, MGC2603, TENC1, U82311, SHARP, AK023458, EDG1, CYP1A2, C11orf10, ZNRD1, TLP19, SNRPG, FLJ23441, WNT5A, DSTN, C20orf52, NETO2, HNRPC, LEREPO4, RPL37, RPC32, NHP2L1, COX7A2L, RPS29, DCLRE1A, TRIP15, TRIP3, ANLN, NF2, PTPRN2, KIAA1287, FLJ20531, RUFY2, RPL5, PSMD1, KIAA0152, FLJ21103, FLJ20186, FLJ13611, RFC3, NM_002807, NM_014730, AK024756, AL157465, AK023673, NM_002915, NM_018613, ZNF92, CPNE3, SUPT16H, MAD1L1 ) |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Biomarker for early detection of liver cancer and validated on independent dataset |
| Experimental Condition | Dysplastic nodules of HCC v/s Edmondson grade 1 |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Discriminating among early-stage samples (between LGDN, HGDN and G1) |
| Level of significance | p < 0.001 |
| Source | Tissue |
| PMID | 16175600 |
| Type of Biomarker | Prognostic |
| Pathway | NA |
| Cohort | Training dataset:42 Primary HCCs,:30 HCCs (10 G1 [Edmondson grade 1 ], 10 G2 [Edmondson grade 2], and 10 G3 [Edmondson grade 13]), 10 LGDNs, and 10 HGDNs [premalignant lesions or dysplastic nodules of HCC] ; validation dataset : 14 samples (5 new samples and the 9 samples excluded from study) |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | 95% |
| AUC | NA |
| Disease | Dysplastic nodules of HCC v/s Edmondson grade 1 |
| Year of Publication | 2005 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |